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Brain glioblastoma remains an incurable disease. The median
survival following surgery is less than 4 months, while additional
radiotherapy slightly improves the survival figures (Miller et al,
1990; Davis et al, 1998; Nakagawa et al, 1998). Hyperfractionated
and/or accelerated radiotherapy with or without chemotherapy
may be of value (Fine et al, 1993; Nelson et al, 1993). The
blood–brain barrier is considered a major obstacle for chemothera-
peutic drugs to efficiently reach the tumour. Exposure of glio-
blastoma cells to a higher concentration of drugs may be achieved
using compounds that disrupt the blood–brain barrier, such as
mannitol (Gumerlock et al, 1992; Doolittle et al, 1998). The inad-
equate concentration of chemotherapeutic drugs in metastatic
brain tumours is also related to this barrier and indeed, radio-
therapy alone is the standard modality for the treatment of central
nervous system metastasis, the systemic chemotherapy being not
effective even for chemosensitive tumours (Jayson and Howell,
1996).
Doxorubicin is one of the most effective drugs for the two prin-
cipal sources of brain metastasis, namely breast and lung cancer
(Valdivieso et al, 1984; Paridaens, 1998). In vitro data show that
glioblastoma cell lines are also sensitive to doxorubicin, although
overexpression of multidrug-resistance related proteins may
counteract the efficacy of the drug (Abe et al, 1994; Stan et al,
1999). The radiosensitizing effects of anthracyclines are well
known (Sherman et al, 1982; Bonner and Lawrence, 1990).
Recently, a novel formulation of doxorubicin, the so-called
Stealth® liposomal doxorubicin (Caelyx®) entered the clinical
practice. Stealth® liposomal technology allows a prolonged circu-
lation half-life time of the encapsulated drugs, the liposome size
and structure being a major obstacle for extravasation (Gabizon
et al, 1994). In that way, the carried drug is selectively accumu-
lated in tissues with increased vascular permeability, such as
tumoural tissue (Working et al, 1994). In vivo studies show that
liposomes are indeed highly accumulated in experimental gliomas
(Shibata et al, 1990; Siegal et al, 1995) suggesting that liposomal
drugs may effectively overcome the blood–brain barrier. On the
other hand, liposomal doxorubicin, unlike the free doxorubicin, is
equally effective in cells with or without multidrug resistance
protein expression (Rahman et al, 1992), showing that liposomal
technology may also be useful in overcoming inherent resistance
of cancer cells to doxorubicin and to other drug substrates of
p-glycoprotein efflux pump activity (Warren et al, 1992).
In the present study we investigated the accumulation of radio-
labelled stealth® liposomal doxorubicin in patients with glioblas-
tomas and with metastatic brain tumours undergoing radiotherapy.
A high intratumoural accumulation is reported, which renders
liposomal doxorubicin a candidate for chemo-radiotherapy com-
binations.
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Summary The blood–brain barrier is a major obstacle for the chemotherapeutic drugs to effectively reach primary or secondary brain
tumours. Stealth® liposomal drugs are highly accumulated in tumoural tissues. In the present study we investigated the relative accumulation
of 99mTc-DTPA radiolabelled stealth® liposomal doxorubicin (Caelyx®) in 10 patients with metastatic brain tumours and five patients with brain
glioblastoma undergoing radiotherapy. Patients with metastatic brain lesions were treated with 10 consecutive fractions of radiotherapy
(whole brain, 3 Gy/fraction, day 1–12) followed by a booster dose of 9 Gy (3 Gy/fraction, day 21–23). Caelyx®, at a dose of 25 mg mg–2 was
given on day 1 and on day 21. Radiolabelled Caelyx® accumulation was 13–19 times higher in the glioblastomas and 7–13 times higher in
the metastatic lesions, as compared to the normal brain. The drug accumulation in the tumoural areas was 40–60% of the accumulation in the
bone marrow of the skull bones. The normal brain radioactivity was <4% of the bone marrow, confirming an important shielding effect of the
blood–brain barrier in the normal but not in the tumoural tissue. Four of 10 patients with metastatic lesions showed a complete response in
CT-scan performed 2 months following therapy. There was no severe toxicity related to radiotherapy or to chemotherapy noted. It is
concluded that stealth® liposomal drugs selectively overcome the blood–brain barrier in the tumoural areas. The clinical importance of this
observation is now under investigation. © 2000 Cancer Research Campaign
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Ten patients with brain metastasis entered a phase I/II study of
radiotherapy and concomitant administration of stealth® lipo-
somal doxorubicin (Caelyx®; ALZA Corporation, Palo Alto CA,
USA). The aims of the study were to investigate the relative accu-
mulation of the radiolabelled Caelyx® in tumour and normal brain
areas, as well as the feasibility of Caelyx® combination with brain
irradiation. Five more patients with histologically diagnosed brain
glioblastoma, treated in an ongoing dose-escalation phase I/II
Caelyx®-based chemo-radiotherapy protocol, were also assessed
for Caelyx® distribution.
Recruitment criteria
The criteria for inclusion into the therapeutic protocol were
patients with histologically confirmed cancer and limited brain
metastatic disease (≤ two lesions), assessed with and measurable
on CT-scan or MRI, following typical neurologic symptoma-
tology. Patients with performance status >2. were excluded.
Patients with white blood cells <2500 ml–1, platelets <120 000 ml–1
or haemoglobin <10 g/dl–1 were excluded. Pregnant women or
patients with major heart, lung, liver, renal or psychiatric disease,
or with haematological malignancies, were excluded. Written
informed consent was obtained from all patients.
Caelyx® radiolabelling and scintigraphic imaging
procedure
Five mg of Caelyx® (2.5 ml from the commercially available
formulation) were incubated with 20 mCi of 99mTc-DTPA for
20 min. The labelling efficiency and the radiochemical purity of
the 99mTc-DTPA-labelled Caelyx® was determined by instant thin-
layer chromatography (ITLC) on 2 ´ 20 cm chromatography strips
as previously described (Koukourakis et al, 1999). Briefly, for the
labeling method employed for Caelyx®, ITLC indicated a
labelling efficiency of 80%. The main labelled species migrate
with the solvent front of the second solvent, while about 19% of
the radioactivity, considered as reduced uncomplexed 99mTc (O2),
remains at the origin. Less than 1% of the radioactivity, corre-
sponding to free pertechnate 99mTc(O4), migrates with the solvent
front of the first solvent.
Radiolabelled Caelyx® was thereafter diluted in 50 ml dextrose
water (DW) and was given as a 5 min infusion before the first frac-
tion of radiotherapy. Two hours later, the patient underwent planar
(5 min) and SPECT (20 min) scintigraphy using a single-head
SPECT camera. Standard regions of interest (ROIs) were drawn
on the SPECT images in both the tumour and the corresponding
normal brain region of the contralateral hemisphere. Equal ROIs
were also drawn on the skull areas. These areas show the accumu-
lation of the liposomal drug in the bone marrow of the skull bones.
Caelyx® chemotherapy
Following the scintigraphy, patients with metastatic brain tumours
were transferred to the chemotherapy unit and an additional dose
of 20 mg m2 diluted in 250 ml DW was infused for 30 min. The
first fraction of radiotherapy was given 1 h after the Caelyx® infu-
sion. An additional dose of 25 mg m–2 of Caelyx® was given on
day 21 (when booster fields of radiotherapy were to be treated).
Patients with glioblastoma were recruited in an ongoing phase I
therapeutic protocol of chemoradiotherapy with Caelyx®-based
chemotherapy.
Radiotherapy for brain metastases
Patients with brain metastases received whole-brain irradiation of
30 Gy (10 fractions of 3 Gy, five fractions per week; days 1–12).
An additional dose of 9 Gy (three consecutive fractions of 3 Gy)
was given, starting on day 21, with multiple booster fields directed
to the metastatic lesions.
Toxicity evaluation
The toxicity to both chemotherapy and radiotherapy was recorded
clinically twice a week, while whole blood cell count, serum urea
and creatinine, and liver enzymes were analysed every 2 weeks
during the radiotherapy period and for 4 weeks thereafter.
Deterioration of the symptomatology during therapy was to be
immediately followed by MRI scan to assess whether there
was intra-tumoural haemorrhage or increased brain oedema. The
World Health Organization toxicity scale was used to record acute
toxicity (WHO, 1979). The median follow-up of patients was
6 months (2–12 months).
Response evaluation of brain metastases
Response to treatment of metastatic brain tumours was assessed
with a computed tomography scan (or MRI scan) on days 18–20
(before the booster fields) and 45–60 days following treatment
completion. CT scan was done every 2 months for the first 6
months and every 3 months (or earlier if indicated by symptom-
atology) thereafter. Complete response (CR) was defined as the
disappearance of all measurable lesions within 2 months following
treatment completion, lasting for at least 2 months after response
documentation. Partial response (PR) was defined as a 50–95%
reduction in tumour size, while all other cases were considered as
non-responders (NR).
RESULTS
Drug distribution
Planar and SPECT scintigraphy revealed an intense accumulation
of the drug in the tumours for all 15 cases examined (six non-small
cell lung carcinomas, one colorectal, three breast carcinomas
and five glioblastomas). Figures 1A and 1B show the 99mTc-
DTPA–Caelyx® SPECT image and the related MRI tomogram
respectively, of a small metastatic lesion from a lung adenocarci-
noma to the thalamus invading the third ventricle. Despite the
small dimensions, an intense accumulation of the radiolabelled
Caelyx® is noted. Figures 1C and 1D show the SPECT and the
CT-scan image respectively of a glioblastoma of the temporal
lobe.
Table 1 shows the total counts from ROIs and count ratios
obtained from each analysed case. Overall, the tumour to normal
brain ratio was 16 ± 3 and 10 ± 3 for glioblastoma and metastatic
tumours, respectively. The drug accumulation was significantly
higher in glioblastomas (P = 0.01). These results show that stealth
liposomal doxorubicin accumulation is 13–19 times higher in the
glioblastoma and 7–13 times higher in metastatic tumours, as
compared to the normal brain tissue.
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Figure 1 99mTc-DTPA-Caelyx® SPECT image and the related MRI tomogram of a small metastatic lesion from a lung adenocarcinoma to the thalamus
(A and B respectively). SPECT and the CT-scan image of a glioblastoma of the temporal lobe (C and D respectively)The drug accumulation in the normal brain was less than 4% of
the drug accumulated in the bone marrow, showing a dramatic
shielding effect of the blood–brain barrier. On the contrary, the
stealth liposomal doxorubicin accumulation in the tumoural areas
was very close to the bone marrow accumulation (60% and 40% of
the concentration assessed in the bone marrow, for glioblastomas
and metastatic tumours, respectively).
Response and toxicity in patients treated for metastatic
brain disease
Complete response was documented in four of 10 of patients (two
breast and two non-small cell lung carcinomas) two months
following the end of chemo-radiotherapy. Another four patients
(one breast and three non-small cell lung carcinomas) showed
partial response. There was no haematological toxicity related to
Caelyx®. No mucositis was noted. One patient complained of dry
palmar skin desquamation but no severe erythrodysestesia was
noted in any of the patients. Radiotherapy was accomplished
without any increase of early reactions from the irradiated skin and
there was no acute neurological toxicity noted. Up to now (median
follow-up 6 months) no patient with delayed reactions, such as
demyelination or brain necrosis, has been observed.
DISCUSSION
Pegylated liposomes bear a tightly packed semisolid phospholipid
layer and are coated with short polyethylene glycol chains. This
formulation enables liposomes to escape from macrophage phago-
cytosis (Lasic et al, 1991) and to circulate with a median half-life
of 45–55 h. Stealth liposomes, being larger than erythrocytes, tend
to accumulate in tumoural tissues, since a leaky vascularization
allows the liposome extravasation into the stroma (Dvorak et al,
1988). Prolonged circulation of the drug results in continuous
selective accumulation in tumours as compared to normal tissues
(Stewart and Harrington, 1997). Following their extravasation
physico-chemical destabilization and subsequent breakdown of
the liposomal envelope is effected as a result of a constellation of
local conditions, such as the low pH (Sakayama et al, 1994), the
presence of lipases released from dying neoplastic cells (Warren
et al, 1992) and also the release of various enzymes or oxidizing
molecules and radicals by tumour-infiltrating inflammatory cells
(Cobbs et al, 1995; Koukourakis et al, 1998). The cytotoxic effect
of radiotherapy may therefore further contribute to the establish-
ment of intra-tumoural conditions that rapidly break down the
extravasated liposomes. Stealth liposomal drug combination with
radiotherapy is therefore founded on a strong theoretical back-
ground. Indeed, experimental studies show a substantial enhance-
ment of the efficacy of fractionated radiotherapy by stealth
liposomal drugs including doxorubin (Harrington et al, 1998).
Although certain very chemosensitive tumours that are
metastatic to the brain (such as gestational tumours) can be cured
with chemotherapy, the overall response rates of metastatic brain
tumours are lower than the ones documented for the primary
lesions of origin. This shows that, apart from the chemoresistance
related to the cancer cell biology itself, the blood–brain barrier
may further reduce the efficacy of chemotherapy by inhibiting the
achievement of adequate drug concentrations in brain tumours.
Several experimental studies suggest that liposomal technology
may be of importance in overcoming the blood–brain barrier.
Shibata et al (1990) reported a study where liposomes containing
horse-radish peroxidase were injected in glioblastoma-bearing
rats. Histochemical staining showed that 30 min following injec-
tion the liposomes were highly accumulated in and around the
tumour endothelium, but also within tumour cells (Shibata et al,
1990). In another study, Siegal et al (1995) also reported an up to
30-fold higher accumulation of stealth liposomal doxorubicin in
the cerebrospinal fluid of rats bearing an inoculated to the brain
sarcoma as compared to the concentrations achieved with free
doxorubicin. Liposome-encapsulated taxol was also found to be
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Table 1 Total counts in standard regions of interest (ROIs) and count ratios obtained in brain tumour (T), normal brain (NB) and bone marrow of the skull
bones (BM), following intravenous injection of 5 mg of 99m-Tc-DTPA radiolabelled stealth liposomal doxorubicin
Patient No/
Counts in ROIs Count ratio
Disease T NB BM T/NB T/BM NB/BM
Glioblastoma
(location)
1 temporal 39 2.5 83 15.6 0.47 0.03
2 occipital 29 2.4 48 12.0 0.60 0.05
3 frontal/temporal 42 1.9 55 22.1 0.76 0.03
4 frontal 32 2.1 54 15.2 0.59 0.03
5 frontal/temporal 37 2.4 62 15.4 0.59 0.03
Overall (mean ± SD) 35 ± 5 2.2 ± 0.2 60 ± 13 16 ± 3 0.6 ± 0.1 0.03 ± 0.001
Brain metastasis
(primary)
1 NSCLC 18 2.0 56 9.0 0.32 0.03
2 NSCLC 32 2.4 42 13.3 0.76 0.05
3 NSCLC 19 2.2 29 8.6 0.65 0.07
4 NSCLC 31 2.6 52 11.9 0.59 0.05
5 NSCLC 26 2.2 62 11.8 0.41 0.03
6 NSCLC 15 2.0 45 7.5 0.33 0.04
7 Colorectal 8 2.6 47 3.0 0.17 0.05
8 Breast 30 1.9 61 15.7 0.49 0.03
9 Breast 33 2.3 59 14.3 0.55 0.04
10 Breast 29 2.6 58 11.1 0.50 0.04
Overall (mean ± SD) 24 ± 8 2.2 ± 0.2 51 ± 10 10 ± 3 0.4 ± 0.1 0.04 ± 0.004more effective than free taxol in two brain tumours xenografted
into nude mice (Riondel et al, 1992). More recently, Khalifa et al
(1997) examined the distribution of 111In-labelled liposomes in
patients with glioblastoma, showing a remarkable increased accu-
mulation in the tumours as compared to normal brain. This differ-
ential accumulation rate was increasing even 72 h following the
administration of liposomes.
The present study confirms an intense accumulation of radio-
labelled 99mTc-DTPA–Caelyx® in patients with glioblastomas and
metastatic tumours of the brain. The tumour to normal brain count
ratio showed a 7–19-fold higher accumulation of the drug in
the tumoural as compared to the normal brain tissue. The drug con-
centration in the tumour was 40–60% of that recorded in the
bone marrow, an area where liposomes are highly accumulated
(Gabizon et al, 1994). The blood–brain barrier shielding effect was
confirmed in the normal brain tissue, where the drug accumulation
was less than 4% of that noted in the bone marrow.
Another observation was the higher accumulation of the drug in
glioblastomas as compared to the metastatic tumours. This may be
explained by pathological studies showing that glioblastomas are
among the tumours of highest vascularization (Plate and Risau,
1995). Indeed in a previous study of ours, highly vascularized
NSCLC showed a higher accumulation of radiolabelled Caelyx®
(Koukourakis et al, 1999). Highly angiogenic gliomas are also
associated with a worse prognosis (Leon et al, 1996). Combination
of radiotherapy with drugs the accumulation of which depends on
the vascular density, may therefore be important for the treatment
of highly angiogenic gliomas.
It is concluded that stealth liposomal drugs selectively over-
come the blood–brain barrier in the tumoural areas. The 7–19-fold
higher accumulation of stealth liposomal doxorubicin in both
glioblastomas and metastatic tumours of the brain strongly
suggests that Caelyx® may increase the effectiveness of radio-
therapy for brain tumours. Clinical studies are ongoing to estab-
lish a well tolerated, high-dose intensity schedule of Caelyx®
chemoradiotherapy and to assess eventual benefit from such a
regimen.
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